Gossamer Bio GOSS 深 滬
等待開盤 06-25 09:30:00 美东时间
0.169
-0.002
-1.40%
華盛通- 最 高0.1813
- 今 開0.1712
- 成交量 1228.75万股
- 最 低 0.168
- 昨 收 0.1714
- 總市值 8261.51万
- 52周最高 3.87
- 市盈率 靜 --
- 換手率 2.51%
- 52周最低 0.14
- 委 比 -93.54%
- 總股本 4.89亿
- 歷史最高 27.15
- 量 比 0.77
- 振 幅 7.76%
- 歷史最低 0.14
- 每 手 1
- 風險率 1.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gossamer Bio Completes Debt Exchange, Converting $181M Of 2027 Notes Into New Secured Notes And Equity
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today ...
06-17 20:15
快讯 | Gossamer Bio, Inc.宣布就现有可转换票据的交换要约及同意征求的最终收购结果
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consen...
06-17 20:00
快讯 | Gossamer Bio - $1.811亿 的现有可转换票据已于2026年6月2日提交要约收购
Gossamer Bio - $181.1 Mln of Existing Convertible Notes Tendered as of June 2, ...
06-17 20:00
快讯 | Gossamer Bio——取消现有票据中大部分限制性契约和违约事件
Gossamer Bio - Eliminates Most Restrictive Covenants and Events of Default on E...
06-17 20:00
Gossamer Bio收纳斯达克退市警告，核心药物试验失败存多重风险
经济观察网 Gossamer Bio(GOSS.US)面临退市风险、财务压力及药物研发困境，多重因素导致公司当前处于发展关键节点。 近期事件： 公司因股价持续低...
06-11 21:54
Harbour BioMed appoints Luisa Salter-Cid as scientific advisor
Harbour BioMed appoints Luisa Salter-Cid as scientific advisor HBM Holdings named immunology and immuno-oncology executive Luisa Salter-Cid as scientific advisor on June 10, 2026. Salter-Cid is a venture partner at Osage University Partners. She previously served as chief scientific officer of Pione
06-11 09:52
Gossamer Bio shareholders reaffirm board and governance structure
Gossamer Bio ( ($GOSS) ) has shared an announcement. At its 2024 annual meeting...
06-05 18:46
Gossamer Bio Restructures Capital Through Convertible Notes Exchange
The latest announcement is out from Gossamer Bio ( ($GOSS) ). On June 3, 2026, ...
06-05 18:38
Gossamer Bio shareholders re-elect Hasnain, Cox to board as Class II directors
Gossamer Bio shareholders re-elect Hasnain, Cox to board as Class II directors At its annual shareholder meeting, Gossamer Bio re-elected Faheem Hasnain and Russell Cox as Class II directors for terms expiring in 2029. Shareholders ratified Ernst & Young as independent registered public accounting f
06-05 18:03
Gossamer Bio Extends Early Deadline in Note Exchange
Gossamer Bio ( ($GOSS) ) has shared an update. On June 2, 2026, Gossamer Bio, I...
06-02 20:43
